Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Severity in Value Assessment: From Principle to Practice
24 March 2022
There is a wealth of evidence showing societal support to prioritise interventions for severe illnesses and a number of robust methods enabling to reflect this in…
NICE’s severity modifier: a step in the right direction, but still a long way to go
23 March 2022
This blog post is the fifth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
This blog post is the fourth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
Carer quality of life impacts can be included in health technology evaluations, however little guidance is provided. NICE considered providing more guidance as part of their…
To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement
2 March 2022
This blog post is the second in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
Rare Disease Day 2022
28 February 2022
World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
OHE opens a series of blog posts on the NICE new health technology evaluation manual. The blogs will provide a critical discussion around the topics, including the…
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
Opportunity Cost in Health Care: a Favourite Research Topic for OHE
23 November 2021
OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The…